Total Payments
$38,654
2024 Payments
$1,993
Companies
81
Transactions
1,613
Medicare Patients
7,614
Medicare Billing
$3.0M
Payment Breakdown by Category
Food & Beverage$23,291 (60.3%)
Other$13,060 (33.8%)
Consulting$1,150 (3.0%)
Travel$1,053 (2.7%)
Education$100.34 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $23,291 | 1,594 | 60.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,060 | 7 | 33.8% |
| Consulting Fee | $1,150 | 1 | 3.0% |
| Travel and Lodging | $1,053 | 4 | 2.7% |
| Education | $100.34 | 7 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $15,632 | 105 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,146 | 159 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,045 | 120 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,680 | 125 | $0 (2024) |
| Seagen Inc. | $1,479 | 25 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,459 | 113 | $0 (2024) |
| Amgen Inc. | $1,250 | 108 | $0 (2024) |
| Janssen Biotech, Inc. | $1,175 | 84 | $0 (2024) |
| Incyte Corporation | $963.69 | 66 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $791.49 | 59 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,993 | 117 | AstraZeneca Pharmaceuticals LP ($312.77) |
| 2023 | $2,006 | 117 | AstraZeneca Pharmaceuticals LP ($202.76) |
| 2022 | $1,696 | 118 | Novartis Pharmaceuticals Corporation ($196.77) |
| 2021 | $2,980 | 122 | Seagen Inc. ($1,220) |
| 2020 | $2,270 | 170 | Amgen Inc. ($257.60) |
| 2019 | $4,549 | 341 | Merck Sharp & Dohme Corporation ($540.77) |
| 2018 | $4,332 | 296 | Genentech USA, Inc. ($903.78) |
| 2017 | $18,829 | 332 | Genentech USA, Inc. ($14,264) |
All Payment Transactions
1,613 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/18/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.49 | General |
| 12/13/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $19.58 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $11.36 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Oncology | ||||||
| 12/05/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.65 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Monoclonal Antibody | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: Oncology | ||||||
| 11/20/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.05 | General |
| Category: Hematology/Oncology | ||||||
| 11/12/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Oncology | ||||||
| 10/29/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: BioOncology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.95 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Oncology | ||||||
| 10/22/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 1,795 | 28,508 | $1.6M | $578,763 |
| 2022 | 26 | 1,796 | 34,408 | $2.1M | $779,556 |
| 2021 | 28 | 2,103 | 93,402 | $2.3M | $845,841 |
| 2020 | 30 | 1,920 | 85,809 | $2.4M | $845,636 |
Total Patients
7,614
Total Services
242,127
Medicare Billing
$3.0M
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 346 | 1,445 | $325,125 | $156,218 | 48.0% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 54 | 8,900 | $445,000 | $148,658 | 33.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 3,720 | $148,800 | $68,924 | 46.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 34 | 369 | $129,150 | $44,868 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 123 | 123 | $61,500 | $23,545 | 38.3% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 23 | 3,440 | $86,000 | $21,061 | 24.5% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 30 | 775 | $77,500 | $17,661 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 42 | 168 | $29,400 | $17,405 | 59.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 326 | 1,394 | $20,910 | $11,684 | 55.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 322 | 1,372 | $54,880 | $10,418 | 19.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 18 | 124 | $15,500 | $8,079 | 52.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 26 | 286 | $35,750 | $7,661 | 21.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 65 | 511 | $25,550 | $6,188 | 24.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 37 | 131 | $9,825 | $5,651 | 57.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 57 | 93 | $18,600 | $5,492 | 29.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 33 | $9,075 | $4,982 | 54.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 82 | $16,400 | $4,974 | 30.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 31 | $9,300 | $4,945 | 53.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 44 | 304 | $22,800 | $4,293 | 18.8% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 30 | 32 | $6,400 | $2,276 | 35.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 30 | 36 | $3,600 | $1,841 | 51.2% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 18 | 1,590 | $23,850 | $1,339 | 5.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 20 | 3,280 | $16,400 | $320.90 | 2.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 28 | 152 | $1,520 | $179.70 | 11.8% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 35 | 117 | $234.00 | $97.97 | 41.9% |
About Christopher Tully
Christopher Tully is a Hematology & Oncology healthcare provider based in Mountain Lakes, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2008. The National Provider Identifier (NPI) number assigned to this provider is 1053585232.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christopher Tully has received a total of $38,654 in payments from pharmaceutical and medical device companies, with $1,993 received in 2024. These payments were reported across 1,613 transactions from 81 companies. The most common payment nature is "Food and Beverage" ($23,291).
As a Medicare-enrolled provider, Tully has provided services to 7,614 Medicare beneficiaries, totaling 242,127 services with total Medicare billing of $3.0M. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology
- Location Mountain Lakes, NJ
- Active Since 04/17/2008
- Last Updated 02/11/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053585232
Products in Payments
- Avastin (Biological) $7,913
- TECENTRIQ (Biological) $6,668
- OPDIVO (Biological) $1,623
- KEYTRUDA (Biological) $1,521
- PADCEV (Biological) $1,297
- JAKAFI (Drug) $828.18
- KISQALI (Drug) $536.86
- LYNPARZA (Drug) $521.31
- DARZALEX (Biological) $477.35
- Lenvima (Drug) $444.80
- CALQUENCE (Drug) $422.41
- Stivarga (Drug) $381.22
- IMFINZI (Drug) $376.29
- ZEJULA (Drug) $374.09
- Nplate (Biological) $361.05
- ADCETRIS (Biological) $347.76
- Imbruvica (Drug) $324.55
- EMPLICITI (Biological) $295.72
- Enhertu (Drug) $291.19
- Nerlynx (Drug) $264.66
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Mountain Lakes
Dr. Muhammad Abbasi, M.d, M.D
Hematology & Oncology — Payments: $33,999
Hematology & Oncology $33,999
Jason Levitz, M.d, M.D
Hematology & Oncology — Payments: $24,538
Hematology & Oncology $24,538
Naveed Jan, M.d, M.D
Hematology & Oncology — Payments: $23,098
Hematology & Oncology $23,098
Dr. Ruby Hanna, M.d, M.D
Hematology & Oncology — Payments: $11,389
Hematology & Oncology $11,389